The global Liver Cirrhosis Treatment market garnered revenue around USD XX Billion in 2019 and projected to reach USD 1350 Million in 2027, with at a compound annual growth rate of 5.5% throughout the estimate period from 2020 to 2027.
Liver cirrhosis is a disease in which the liver is severely damaged and scarred, hence leading to liver failure. A lot of research activities are being carried out by major pharmaceutical companies to develop novel drugs for the treatment of liver cirrhosis. Rapidly changing lifestyle is increasing the risk of people suffering from liver cirrhosis. Moreover, people suffering from hepatitis, cystic fibrosis, syphilis, alpha-1 antitrypsin deficiency, alcohol abuse, and other liver diseases are at greater risk of suffering from liver cirrhosis. As of 2015, 887,000 deaths people died suffering from hepatitis B. Most of these deaths were because these patients were suffering from liver cirrhosis and hepatocellular carcinoma (primary liver cancer) along with hepatitis B.
The increasing prevalence of liver cirrhosis expected to contribute to the growth of the market in the near future.
Growing awareness programs regarding liver diseases
Rising R&D investment for the development of innovative drugs for liver diseases
Stringent government regulations
High investment required for drug research and development
Side-effects of medications prescribed for liver cirrhosis
This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.
The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the Liver Cirrhosis Treatment market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the Liver Cirrhosis Treatment market growth.
The global Liver Cirrhosis Treatment market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.
Major manufacturers analysed under this study comprises:
Pfizer, Inc. (US)
Merck & Co., Inc. (Germany)
Novartis AG (Switzerland)
Hoffmann-La Roche Ltd (Switzerland)
Takeda Pharmaceutical Company Limited (Japan)
Gilead Sciences, Inc. (US)
AstraZeneca (UK)
Bayer AG (Germany)
Sanofi (France)
Shionogi Inc. (Japan)
Promethera (Belgium)
This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:
By Treatment
Antibiotics:
Immunosuppressants:
Others:
By End-User
Hospitals and Clinics
Research and Academic Institutes:
Others:
Regional Analysis and Forecast
Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope:
North America
? U.S.
? Canada
Europe
? Germany
? U.K.
? Italy
? France
? Rest of EU
Asia Pacific
? China
? India
? Japan
? Southeast Asia
? Rest of APAC
Central & South America
? Brazil
? Argentina
? Rest of Central & South America
Middle East and Africa
? UAE
? Saudi Arabia
? Rest of MEA